CURRENT TREATMENT OPTIONS FOR INVASIVE ASPERGILLOSIS

Imagem de Miniatura
Arquivos
art_BATISTA_CURRENT_TREATMENT_OPTIONS_FOR_INVASIVE_ASPERGILLOSIS_2013.PDF (231.32 KB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PROUS SCIENCE, SAU-THOMSON REUTERS
Autores
MOSS, R. B.
Citação
DRUGS OF TODAY, v.49, n.3, p.213-226, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Invasive pulmonary aspergillosis is a major cause of morbidity and mortality in immunocom promised patients, particularly those with hematological malignancies in the setting of profound neutropenia and/or hematopoietic stem cell transplant recipients. The optimal therapy for invasive aspergillosis relies on the restoration of leukocyte counts and effective antifungal treatment initiated at the earliest stage of infection. Several alternative antifungal compounds are currently available. A rational approach should take into account not only the degree of certainty of infection (as codified by the EORTC/MSG classification), but also previous exposure to other antifungals, the pharmacokinetic and pharmacodynamic characteristics of the antifungals employed and the clinical characteristics of the patient.
Palavras-chave
Invasive aspergillosis, Antifungal therapy, Antifungal drugs, Voriconazole, Caspofungin, Amphotericin B, Immunocompromised hosts, Polyene antibiotics, Azoles, Echinocandins, Invasive fungal infection
URI
https://observatorio.fm.usp.br/handle/OPI/1967
Referências
  1. Auberger J, 2012, J ANTIMICROB CHEMOTH, V67, P2268, DOI 10.1093/jac/dks189
  2. Bergeron A, 2012, J CLIN MICROBIOL, V50, P823, DOI 10.1128/JCM.00750-11
  3. Blot F, 2002, NEW ENGL J MED, V347, P2080
  4. Bohme A, 2009, ANN HEMATOL, V88, pCP6, DOI 10.1007/s00277-008-0622-5
  5. Bowden R, 2002, CLIN INFECT DIS, V35, P359, DOI 10.1086/341401
  6. Caillot D, 2003, ACTA HAEMATOL-BASEL, V109, P111, DOI 10.1159/000069281
  7. Caillot D, 2007, CANCER, V110, P2740, DOI 10.1002/cncr.23109
  8. Cappelletty D, 2007, PHARMACOTHERAPY, V27, P369, DOI 10.1592/phco.27.3.369
  9. Cornely OA, 2007, NEW ENGL J MED, V356, P348, DOI 10.1056/NEJMoa061094
  10. Cornely OA, 2007, CLIN INFECT DIS, V44, P1289, DOI 10.1086/514341
  11. DENNING DW, 1994, AM J MED, V97, P135, DOI 10.1016/0002-9343(94)90023-X
  12. Denning DW, 2006, J INFECTION, V53, P337, DOI 10.1016/j.jinf.2006.03.003
  13. De Pauw B, 2008, CLIN INFECT DIS, V46, P1813, DOI 10.1086/588660
  14. Diaz-Guerra TM, 2003, ANTIMICROB AGENTS CH, V47, P1120, DOI 10.1128/AAC.47.3.1120-1124.2003
  15. Douglas CM, 2001, MED MYCOL, V39, P55, DOI 10.1080/744118880
  16. Ellis M, 1998, CLIN INFECT DIS, V27, P1406, DOI 10.1086/515033
  17. Feola D, 1997, CLIN INFECT DIS, V25, P344
  18. GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301
  19. Graf K, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-163
  20. Herbrecht R, 2002, NEW ENGL J MED, V347, P408, DOI 10.1056/NEJMoa020191
  21. Howard SJ, 2009, EMERG INFECT DIS, V15, P1068, DOI 10.3201/eid1507.090043
  22. Ide L, 2004, CLIN MICROBIOL INFEC, V10, P862, DOI 10.1111/j.1469-0691.2004.00945.x
  23. Jantunen E, 1997, BONE MARROW TRANSPL, V19, P801, DOI 10.1038/sj.bmt.1700737
  24. Johnson JR, 2002, NEW ENGL J MED, V346, P1745, DOI 10.1056/NEJM200205303462213
  25. Karthaus M, 2002, NEW ENGL J MED, V347, P2080
  26. Kontoyiannis DP, 2005, CANCER, V103, P2334, DOI 10.1002/cncr.21057
  27. Kontoyiannis DP, 2005, NEW ENGL J MED, V352, P410
  28. Kontoyiannis DP, 2010, CLIN INFECT DIS, V50, P1091, DOI 10.1086/651263
  29. Leeflang MM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007394
  30. Lellek H, 2011, MYCOSES, V54, P39, DOI 10.1111/j.1439-0507.2010.01985.x
  31. Lin SJ, 2001, CLIN INFECT DIS, V32, P358, DOI 10.1086/318483
  32. Lockhart S.R., 2012, ANTIMICROB AGENTS CH, V55, P4465
  33. Maertens J, 2011, BONE MARROW TRANSPL, V46, P709, DOI 10.1038/bmt.2010.175
  34. Maertens J, 2004, CLIN INFECT DIS, V39, P1563, DOI 10.1086/423381
  35. Marr KA, 2000, BLOOD, V96, P2055
  36. Marr KA, 2004, BLOOD, V103, P1527, DOI 10.1182/blood-2003-08-2644
  37. Marr KA, 2002, NEW ENGL J MED, V346, P278, DOI 10.1056/NEJM200201243460410
  38. Marr KA, 2002, CLIN INFECT DIS, V34, P909, DOI 10.1086/339202
  39. Marr KA, 2004, CLIN INFECT DIS, V39, P797, DOI 10.1086/423380
  40. Masia CM, 2002, LANCET INFECT DIS, V2, P550
  41. Mehta J, 1997, BONE MARROW TRANSPL, V20, P39, DOI 10.1038/sj.bmt.1700842
  42. Mellinghoff IK, 2002, CLIN INFECT DIS, V34, P1648, DOI 10.1086/340522
  43. Metan G, 2013, MYCOSES, V56, P34, DOI 10.1111/j.1439-0507.2012.02195.x
  44. Mihu CN, 2010, CANCER-AM CANCER SOC, V116, P5290, DOI 10.1002/cncr.25312
  45. MILLS W, 1994, BRIT J HAEMATOL, V86, P754, DOI 10.1111/j.1365-2141.1994.tb04825.x
  46. Mortensen KL, 2011, EUR J CLIN MICROBIOL, V30, P1355, DOI 10.1007/s10096-011-1229-7
  47. NG TTC, 1995, ARCH INTERN MED, V155, P1093, DOI 10.1001/archinte.155.10.1093
  48. OPPENHEIM BA, 1995, CLIN INFECT DIS, V21, P1145, DOI 10.1093/clinids/21.5.1145
  49. Pascual A, 2008, CLIN INFECT DIS, V46, P201, DOI 10.1086/524669
  50. Perfect JR, 2003, CLIN INFECT DIS, V36, P1122, DOI 10.1086/374557
  51. PERFECT JR, 1992, J INFECT DIS, V165, P891
  52. PERSAT F, 1992, EUR J CANCER, V28A, P838, DOI 10.1016/0959-8049(92)90127-N
  53. Pitisuttithum P, 2005, J ANTIMICROB CHEMOTH, V56, P745, DOI 10.1093/jac/dki288
  54. Popp A I, 1999, Int J Infect Dis, V3, P157, DOI 10.1016/S1201-9712(99)90038-3
  55. Powers JH, 2002, NEW ENGL J MED, V346, P289, DOI 10.1056/NEJM200201243460414
  56. Prentice AG, 2005, J ANTIMICROB CHEMOTH, V56, P17
  57. Prentice HG, 1997, BRIT J HAEMATOL, V98, P711, DOI 10.1046/j.1365-2141.1997.2473063.x
  58. Purkins L, 2002, ANTIMICROB AGENTS CH, V46, P2546, DOI 10.1128/AAC.46.8.2546-2553.2002
  59. Raad II, 2008, LEUKEMIA, V22, P496, DOI 10.1038/sj.leu.2405065
  60. RINGDEN O, 1991, J ANTIMICROB CHEMOTH, V28, P73
  61. Singh N, 2006, TRANSPLANTATION, V81, P320, DOI 10.1097/01.tp.0000202421.94822.f7
  62. Skiada A, 2011, CLIN MICROBIOL INFEC, V17, P1859, DOI 10.1111/j.1469-0691.2010.03456.x
  63. SLAVIN MA, 1995, J INFECT DIS, V171, P1545
  64. Steinbach WJ, 2003, CLIN INFECT DIS, V37, pS188, DOI 10.1086/376524
  65. Steinbach WJ, 2012, J INFECTION, V65, P453, DOI 10.1016/j.jinf.2012.08.003
  66. Stone JA, 2002, ANTIMICROB AGENTS CH, V46, P739, DOI 10.1128/AAC.46.3.739-745.2002
  67. Tashiro M, 2012, ANTIMICROB AGENTS CH, V56, P584, DOI 10.1128/AAC.05394-11
  68. Theel ES, 2013, MYCOPATHOLOGIA, V175, P33, DOI 10.1007/s11046-012-9579-y
  69. Theuretzbacher U, 2006, CLIN PHARMACOKINET, V45, P649, DOI 10.2165/00003088-200645070-00002
  70. TOLLEMAR J, 1992, DRUG INVEST, V4, P232
  71. Ullmann AJ, 2007, NEW ENGL J MED, V356, P335, DOI 10.1056/NEJMoa061098
  72. Uppin MS, 2011, INDIAN J PATHOL MICR, V54, P344, DOI 10.4103/0377-4929.81634
  73. Upton A, 2007, CLIN INFECT DIS, V44, P531, DOI 10.1086/510592
  74. van Burik JAH, 2004, CLIN INFECT DIS, V39, P1407, DOI 10.1086/422312
  75. van der Linden JWM, 2011, EMERG INFECT DIS, V17, P1846, DOI 10.3201/eid1710.110226
  76. Verweij Paul E, 2012, Ned Tijdschr Geneeskd, V156, pA4458
  77. Walsh TJ, 2002, NEW ENGL J MED, V346, P225, DOI 10.1056/NEJM200201243460403
  78. Walsh TJ, 2008, CLIN INFECT DIS, V46, P327, DOI 10.1086/525258
  79. Walsh TJ, 1999, NEW ENGL J MED, V340, P764, DOI 10.1056/NEJM199903113401004
  80. Walsh TJ, 2004, NEW ENGL J MED, V351, P1391, DOI 10.1056/NEJMoa040446
  81. Walsh TJ, 1998, CLIN INFECT DIS, V26, P1383, DOI 10.1086/516353
  82. White MH, 1998, CLIN INFECT DIS, V27, P296, DOI 10.1086/514672
  83. White MH, 1997, CLIN INFECT DIS, V24, P635
  84. Wingard JR, 2010, BLOOD, V116, P5111, DOI 10.1182/blood-2010-02-268151

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/48
Artigos e Materiais de Revistas Científicas - LIM/54